Recurrent Adult Immunoblastic Large Cell Lymphoma Completed Phase 1 Trials for Belinostat (DB05015)

IndicationStatusPhase
DBCOND0028500 (Recurrent Adult Immunoblastic Large Cell Lymphoma)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00348985PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or LymphomasTreatment